Bupropion/zonisamide explained

Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.[1] [2] [3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor. The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.[4] [5]

See also

Notes and References

  1. Web site: Bupropion/Zonisamide - AdisInsight.
  2. Web site: Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half . 2010-01-07 . 2010-01-11 . https://web.archive.org/web/20100111014809/http://www.medicalnewstoday.com/articles/124468.php . dead .
  3. http://www.tesofensine-information.com/empatic.html Empatic Obesity Drug Information and News
  4. Ioannides-Demos LL, Piccenna L, McNeil JJ . Pharmacotherapies for obesity: past, current, and future therapies . Journal of Obesity . 2011 . 179674 . 2011 . 21197148 . 3006492 . 10.1155/2011/179674 . free .
  5. Adan RA . Mechanisms underlying current and future anti-obesity drugs . Trends in Neurosciences . 36 . 2 . 133–40 . February 2013 . 23312373 . 10.1016/j.tins.2012.12.001 . 21974224 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bupropion/zonisamide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.